Invitrogen

c-Met Monoclonal Antibody (3D4)

c-Met Antibody in Immunocytochemistry (ICC/IF)

FIGURE: 1 / 11

c-Met Antibody (18-7366) in ICC/IF

Immunofluorescence analysis of c-Met was done on 70% confluent log phase MKN45 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled c-Met (3D4) Mouse Monoclonal Antibody (187366) at 1:250 dilution in0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution o... View More

c-Met Antibody in Immunohistochemistry (IHC)

c-Met Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P))

Product Image Gallery

c-Met Antibody — IP-MS enrichment of MET (LFQ intensity): MET was enriched 156-fold from BT549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Product # 90409) and c-MET antibody (Product # 18-7366). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. {IP-MS}

Product Details

18-7366

Applications

Tested Dilution

Publications

Western Blot (WB)

View 5 publications 5 publications

Immunohistochemistry (IHC)

View 2 publications 2 publications

Immunohistochemistry (Paraffin) (IHC (P))

Assay-dependent

View 3 publications 3 publications

Immunocytochemistry (ICC/IF)

1:250

View 2 publications 2 publications

ELISA (ELISA)

View 1 publication 1 publication

Miscellaneous PubMed (MISC)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Human, Mouse

Host/Isotype

Mouse / IgG2a

Class

Monoclonal

Type

Antibody

Clone

3D4

Immunogen

Synthetic peptide derived from cytoplasmic domain of human c-Met protein.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Purification

purified

Storage buffer

PBS, pH 7.4, with 1% BSA

Contains

0.1% sodium azide

Storage conditions

4°C

Shipping conditions

Ambient (domestic); Wet ice (international)

AB_2533047

Target Information

MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.

Journal of experimental & clinical cancer research : CR

Bersani F,Picca F,Morena D,Righi L,Napoli F,Russo M,Oddo D,Rospo G,Negrino C,Castella B,Volante M,Listì A,Zambelli V,Benso F,Tabbò F,Bironzo P,Monteleone E,Poli V,Pietrantonio F,Di Nicolantonio F,Bardelli A,Ponzetto C,Novello S,Scagliotti GV,Taulli R

18-7366 was used in Immunohistochemistry to find that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity.

Fri May 12 00:00:00 UTC 2023

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.

PloS one

Muñoz R,Hileeto D,Cruz-Muñoz W,Wood GA,Xu P,Man S,Viloria-Petit A,Kerbel RS

Published figure using c-Met monoclonal antibody (Product # 18-7366) in Immunohistochemistry

Fri Mar 06 00:00:00 UTC 2020

Development of a Novel c-MET-Based CTC Detection Platform.

Molecular cancer research : MCR

Zhang T,Boominathan R,Foulk B,Rao C,Kemeny G,Strickler JH,Abbruzzese JL,Harrison MR,Hsu DS,Healy P,Li J,Pi C,Prendergast KM,Hobbs C,Gemberling S,George DJ,Hurwitz HI,Connelly M,Garcia-Blanco MA,Armstrong AJ

18-7366 was used in immunocytochemistry to elucidate a unique c-MET-based CTC detection platform

Wed Jun 01 00:00:00 UTC 2016

Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.

eLife

Morena D,Maestro N,Bersani F,Forni PE,Lingua MF,Foglizzo V,Šćepanović P,Miretti S,Morotti A,Shern JF,Khan J,Ala U,Provero P,Sala V,Crepaldi T,Gasparini P,Casanova M,Ferrari A,Sozzi G,Chiarle R,Ponzetto C,Taulli R

18-7366 was used in immunohistochemistry - paraffin section and western blot to analyze promotion of development of distinct sarcoma subtypes in hepatocyte growth factor-mediated satellite cells niche disruption

Thu Mar 17 00:00:00 UTC 2016

Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.

eLife

Thu Mar 17 00:00:00 UTC 2016

MET is required for the recruitment of anti-tumoural neutrophils.

Nature

Finisguerra V,Di Conza G,Di Matteo M,Serneels J,Costa S,Thompson AA,Wauters E,Walmsley S,Prenen H,Granot Z,Casazza A,Mazzone M

18-7366 was used in ELISA and western blot to report that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor.

Thu Jun 18 00:00:00 UTC 2015

MET is required for the recruitment of anti-tumoural neutrophils.

Nature

Finisguerra V,Di Conza G,Di Matteo M,Serneels J,Costa S,Thompson AA,Wauters E,Walmsley S,Prenen H,Granot Z,Casazza A,Mazzone M

18-7366 was used in ELISA and western blot to report that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor.

Thu Jun 18 00:00:00 UTC 2015

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).

Oncotarget

Mahadevan D,Theiss N,Morales C,Stejskal AE,Cooke LS,Zhu M,Kurtzman D,Swart R,Ong E,Qi W

187366 was used in western blot to discuss the limitations of c-Kit/PDGFR-targeted therapies for treatment of gastrointestinal stromal tumors

Tue Feb 10 00:00:00 UTC 2015

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Oncology reports

Marchion DC,Bicaku E,Xiong Y,Bou Zgheib N,Al Sawah E,Stickles XB,Judson PL,Lopez AS,Cubitt CL,Gonzalez-Bosquet J,Wenham RM,Apte SM,Berglund A,Lancaster JM

18-7366 was used in Immunocytochemistry experiments to evaluate the role of the hepatocyte growth factor signalling pathway in ovarian cancer cell line chemoresistance and patient survival.

Wed May 01 00:00:00 UTC 2013

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Nature

Straussman R,Morikawa T,Shee K,Barzily-Rokni M,Qian ZR,Du J,Davis A,Mongare MM,Gould J,Frederick DT,Cooper ZA,Chapman PB,Solit DB,Ribas A,Lo RS,Flaherty KT,Ogino S,Wargo JA,Golub TR

18-7366 was used in immunohistochemistry - paraffin section to develop and use a co-culture system to systematically assay the influence of 23 stromal cell types on the innate resistance of 45 cancer cell lines to 35 anticancer drugs.

Thu Jul 26 00:00:00 UTC 2012

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Nature

Straussman R,Morikawa T,Shee K,Barzily-Rokni M,Qian ZR,Du J,Davis A,Mongare MM,Gould J,Frederick DT,Cooper ZA,Chapman PB,Solit DB,Ribas A,Lo RS,Flaherty KT,Ogino S,Wargo JA,Golub TR

Thu Jul 26 00:00:00 UTC 2012

MET and phosphorylated MET as potential biomarkers in lung cancer.

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer

Tretiakova M,Salama AK,Karrison T,Ferguson MK,Husain AN,Vokes EE,Salgia R

18-7366 was used in immunohistochemistry to assess expression and prognostic role of the receptor tyrosine kinase MET, phosphorylated MET, and the ligand hepatocyte growth factor in patients with lung cancer.

Thu Feb 16 00:00:00 UTC 2012

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Cancer research

Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R

18-7366 was used in western blot to study MET receptor tyrosine kinase as a potential novel therapeutic target for head and neck squamous cell carcinoma

Wed Apr 01 00:00:00 UTC 2009

Prognostic significance of c-Met expression in glioblastomas.

Cancer

Kong DS,Song SY,Kim DH,Joo KM,Yoo JS,Koh JS,Dong SM,Suh YL,Lee JI,Park K,Kim JH,Nam DH

187366 was used in immunohistochemistry - paraffin section to test if c-Met expression is associated with overall survival and tumor invasiveness in patients with glioblastomas

Thu Jan 01 00:00:00 UTC 2009

Bioinformatics

Protein Aliases: cMet; EC 2.7.10.1; Hepatocyte growth factor receptor; HGF receptor; HGF-SF receptor; HGF/SF receptor; oncogene MET; Proto-oncogene c-Met; sc MET; Scatter factor receptor; SF receptor; soluble c met; Tyrosine-protein kinase Met

View more View less

Gene Aliases: AUTS9; c-Met; DFNB97; HGFR; MET; RCCP2

View more View less

UniProt ID: (Human) P08581

View more View less

Entrez Gene ID: (Human) 4233

View more View less

Function(s)

protein tyrosine kinase activity hepatocyte growth factor-activated receptor activity protein binding ATP binding protein phosphatase binding

Process(es)

endothelial cell morphogenesis signal transduction cell surface receptor signaling pathway cell proliferation negative regulation of autophagy peptidyl-tyrosine phosphorylation positive regulation of transcription from RNA polymerase II promoter hepatocyte growth factor receptor signaling pathway branching morphogenesis of an epithelial tube positive chemotaxis semaphorin-plexin signaling pathway negative regulation of hydrogen peroxide-mediated programmed cell death positive regulation of endothelial cell chemotaxis

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

c-Met Monoclonal Antibody (3D4)

c-Met Antibody (18-7366) in ICC/IF

Product Details

18-7366

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunocytochemistry (ICC/IF)

ELISA (ELISA)

Miscellaneous PubMed (MISC)

Species Reactivity

Published species

Host/Isotype

Class

Type

Clone

Immunogen

Conjugate

Form

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!